Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage

Molecular Therapy · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles